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Open Forum Infectious Diseases
MAJOR ARTICLE

Joshua P. Havens,1,3 Kimberly K. Scarsi,3 Harlan Sayles,2 Donald G. Klepser,3 Susan Swindells,1 and Sara H. Bares1
1

Division of Infectious Diseases, 2Department of Biostatistics, and 3Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha

Background. Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV
acquisition, yet significant barriers exist to its prescription and use. Incorporating pharmacists in the PrEP care process may help
increase access to PrEP services.
Methods. Our pharmacist-led PrEP program (P-PrEP) included pharmacists from a university-based HIV clinic, a community
pharmacy, and 2 community-based clinics. Through a collaborative practice agreement, pharmacists conducted PrEP visits with potential candidates for PrEP, according to the recommended Centers for Disease Control and Prevention guidelines, and authorized
emtricitabine-tenofovir disoproxil fumarate prescriptions. Demographics and retention in care over 12 months were summarized,
and participant satisfaction and pharmacist acceptability with the P-PrEP program were assessed by Likert-scale questionnaires.
Results. Sixty patients enrolled in the P-PrEP program between January and June 2017 completing 139 visits. The mean age was
34 years (range, 20–61 years), and 88% identified as men who have sex with men, 91.7% were men, 83.3% were white, 80% were
commercially insured, and 89.8% had completed some college education or higher. Participant retention at 3, 6, 9, and 12 months
was 73%, 58%, 43%, and 28%, respectively. To date, no participant has seroconverted. One hundred percent of the participants who
completed the patient satisfaction questionnaire would recommend the P-PrEP program. Pharmacists reported feeling comfortable
performing point-of-care testing and rarely reported feeling uncomfortable during PrEP visits (3 occasions, 2.2%) or experiencing
workflow disruption (1 occasion, 0.7%).
Conclusions. Implementation of a pharmacist-led PrEP program is feasible and associated with high rates of patient satisfaction
and pharmacist acceptability.
Keywords. HIV pre-exposure prophylaxis; HIV prevention; pharmacist-led.

Preventing human immunodeficiency virus (HIV) acquisition
remains a challenge more than 3 decades after the discovery of
the virus. Currently available biomedical HIV prevention approaches include the diagnosis and treatment of HIV, daily oral
HIV pre-exposure prophylaxis (PrEP), and HIV postexposure
prophylaxis. When taken once daily, emtricitabine/tenofovir
disoproxil fumarate (F/TDF) is safe and highly effective in the
prevention of HIV acquisition, but its utilization is limited for
many reasons including lack of patient and provider knowledge
and awareness, treatment access, and stigma [1–3].
There has been much debate about the optimal setting
in which to provide PrEP. Human immunodeficiency virus
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practitioners believe primary care physicians (PCP) are best
suited to prescribe PrEP because of their access to HIVuninfected populations [4]. Although efforts are being made to
educate PCP’s about PrEP, PCP’s are often uncomfortable with
PrEP management [5–7]. Furthermore, in a survey of men who
have sex with men (MSM), 80% stated that they did not want to
talk to their PCP about PrEP [8].
Many areas of the Midwestern United States are designated
as federal medically underserved areas, demonstrating reduced access to primary care services in general and particularly for specialty healthcare services in rural areas. Persons
at risk for HIV acquisition may have difficulty accessing preventive services despite actively seeking PrEP. Furthermore,
1 in 8 PrEP-eligible patients would require greater than 30
minutes of travel to visit a PrEP provider in most rural areas
[9]. Implementation of home-based and telehealth PrEP have
demonstrated some acceptability and feasibility as an alternative to medical clinic-based PrEP [10–13]. With over 60 000
community pharmacies in the United States, representing 13
billion pharmacy visits annually, the community pharmacy
potentially offers an alternative setting to reach individuals at
risk for HIV acquisition [14].
Pharmacist-led HIV PrEP Program • OFID • 1
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Acceptability and Feasibility of a Pharmacist-Led Human
Immunodeficiency Virus Pre-Exposure Prophylaxis
Program in the Midwestern United States

METHODS
Patient Participants

Participants were recruited in the P-PrEP program through selfreferral or referral by friends or partners, their PCP, local HIV/
acquired immune deficiency syndrome (AIDS) service organizations, county sexually transmitted infection (STI) clinics, or
local HIV clinics. Eligibility for P-PrEP inclusion was as follows:
(1) HIV-uninfected patients aged greater than 19 years of age
(the age of majority in Nebraska); (2) at high-risk of acquiring
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HIV (naive or PrEP-experienced) based on 1 or more of the
following risk factors—(a) MSM who engage in condomless
anal intercourse, (b) individuals who are in a serodiscordant
sexual relationship with a known HIV-positive partner, (c)
transgender individuals who engage in condomless intercourse,
(d) individuals engaging in transactional sex, (e) injection drug
users, (e) individuals who use stimulant drugs associated with
high-risk behaviors, such as methamphetamine, (f) individuals
diagnosed (self-reported or by recent STI testing) with at least
1 anogenital STI in the last year, (g) individuals who have ever
been prescribed nonoccupational postexposure prophylaxis
(nPEP) demonstrating continued high-risk behavior or have
used 2 or more courses of nPEP—(3) English-speaking; (4)
serum creatinine less than 1.5 times the upper limit of normal;
(5) nonreactive hepatitis B surface antigen; and (6) no signs
or symptoms of acute HIV infection within the past 30 days.
This study was approved by the University of Nebraska Medical
Center Investigational Review Board, and all participants provided written informed consent.
Participating Pharmacists

Pharmacists at a university-based HIV clinic, a community
pharmacy, a university-based primary care clinic, and a
Federally Qualified Health Center primary care clinic were recruited as P-PrEP pharmacist providers based on proximity and
access to high-risk populations, willingness to participate, and
acceptance by their leadership management team.
Intervention

Pharmacist-led PrEP was designed as a pharmacist-led program
allowing participating pharmacists to serve as PrEP providers
through the utilization of a CPA. A CPA specifying pharmacist responsibilities within the P-PrEP program was completed
between the university-based HIV medical providers and each
participating P-PrEP pharmacist. Each participating P-PrEP
pharmacist completed the National Association of Chain Drug
Stores Point-of-Care certificate program [24]. The P-PrEP
pharmacists were provided additional education on HIV risk
assessment, testing, risk reduction counseling, and administration of PrEP from faculty of the Nebraska AIDS Education and
Training Center located at the University of Nebraska Medical
Center. Upon completion of training, P-PrEP pharmacists assumed responsibility for the PrEP care of individuals enrolled
in P-PrEP through the CPA.
The screening and initial visit was conducted by the P-PrEP
pharmacist at the university-based HIV clinic site to ensure
complete collection of all baseline laboratory tests and consenting procedures. The university-based HIV clinic pharmacist
collected basic demographic and socioeconomic information,
completed a medical history, an HIV risk assessment based on
the study eligibility criteria through conduction of sexual, STI
(self-reported chlamydia, gonorrhea, and syphilis infections),
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Prior studies have demonstrated successful collaboration of
pharmacists with other healthcare providers and health departments in HIV prevention efforts through programs ranging
from HIV screening to pharmacy-based syringe distribution
and postexposure prophylaxis services [15–18]. Individual
states regulate pharmacists’ patient care services through
scope-of-practice laws and related rules. Depending on state
laws, pharmacists may provide an array of patient care services through collaborative practice agreements (CPA) with
medical providers. Collaborative practice agreements create a
formal relationship between a pharmacist and a prescriber and
allow the prescriber to delegate specified patient care responsibilities to the pharmacist under negotiated conditions within
the agreement. Nebraska state law explicitly authorizes CPA,
allowing pharmacists to facilitate and manage a variety of patient care services including point-of-care testing (POCT) and
treatment for bacterial and viral respiratory illnesses, such as
streptococcal pharyngitis and influenza [19, 20]. Building on
these models, a collaborative drug therapy management plan
would allow pharmacists working within the context of a defined HIV PrEP protocol to assume professional responsibility
for all aspects of PrEP administration, including performing
patient assessments, ordering and interpreting laboratory tests,
performing POCT, patient counseling, and dispensing and
monitoring PrEP treatment [21].
Clinical pharmacists have been incorporated into PrEP delivery models in Miami, Florida, and Seattle, Washington [22,
23]. The Miami Veterans Affairs Health System model utilized
pharmacists to optimize adherence and retention in care in between the scheduled quarterly visits but did not incorporate independent pharmacist visits at the quarterly clinical visits. Tung
and colleagues have described a robust pharmacist-led PrEP delivery program, but they are unique in their ability to perform
phlebotomy and other procedures outside the scope of traditional community pharmacies.
This pilot study investigated the acceptability and feasibility
of a pharmacist-led HIV screening and PrEP program (P-PrEP)
for individuals at risk for HIV acquisition in Omaha, Nebraska,
including the number of patients initiated on PrEP, retention
in PrEP care, and patient and pharmacist satisfaction with the
program.

screening (BioPlex 2200 Syphilis Total and RPR Kit; Bio-Rad,
Hercules, CA), were collected by venipuncture in compliance
with standard practices for follow-up visits. If appropriate,
the pharmacist initiated a new 3-month F/TDF prescription
as designated through the CPA bylaws. Follow-up visits were
scheduled for all clinic-based sites but not for the community
pharmacy site. Instead, the participant was able to walk-in to
the community pharmacy at their convenience for the next
quarterly P-PrEP visit.
Study Assessments

The primary outcome measure was the total number of participants initiated on F/TDF for PrEP. Secondary outcome
measures included the following: (1) adherence to F/TDF, (2)
number of patients retained at 3, 6, 9, and 12 months, (3) patient
satisfaction with P-PrEP services, and (4) pharmacist satisfaction with P-PrEP services.
Assessment of adherence to F/TDF while engaged in the
P-PrEP program occurred at each follow-up visit for the preceding 3 months by calculation of a medication possession ratio
(total number of F/TDF doses dispensed/total number of days
between study follow-up visits) [26]. Retention in PrEP care
within the P-PrEP program was determined as the total number
of patients completing follow-up visits at 3, 6, 9, and 12 months.
Protocol-derived questionnaires, designed with Likert-scale
and open-ended questions, to assess participant satisfaction
and pharmacist experience of the P-PrEP program were completed by participants retained at the 6-month visit and at each
visit for the pharmacists. The respondents completed questionnaires independently, and identifying information was not
included on the questionnaires. Participants were asked to describe their P-PrEP experience regarding the quality of PrEP
education provided, interactions with pharmacists, privacy, collection of laboratory specimens, timeliness of follow-up visits,
ease of medication access, and maximal amount participants
would pay for P-PrEP if offered (community pharmacy site
only). Pharmacists were asked to describe their comfort level
with conducting P-PrEP visits and performing POCT. Time requirements for performing POCT, PrEP consultation, and visit
entirety were recorded.
Descriptive statistics were used to summarize all study data
including the participant demographics, baseline characteristics, and participant/pharmacist P-PrEP satisfaction. Survival
analysis via Kaplan-Meier estimators and log-rank tests were
used to evaluate demographic characteristics associated with
retention in PrEP care.
RESULTS
Participant Characteristics

From January 1, 2017 through June 30, 2017, 60 participants
enrolled in the P-PrEP program and started F/TDF. The majority, 91.7% (55 of 60), were men, 83.3% (50 of 60) were white,
Pharmacist-led HIV PrEP Program • OFID • 3
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and substance use histories, PrEP counseling, baseline laboratory testing, and performed HIV and STI screening. If clinical
information such as laboratory testing, STI testing, etc performed at another healthcare facility was needed, the participant signed a Health Insurance Portability and Accountability
Act of 1996 release form to gain access to such data. Eligible
P-PrEP participants were provided a 90-day F/TDF prescription. Each participant was given the option to continue PrEP
care at the university-based HIV clinic or at 1 of the other 3
participating sites (community pharmacy, university-based primary care clinic, or Federally Qualified Health Center primary
care clinic). Primary care services were integrated with PrEP
at the university-based and Federally Qualified Health Center
primary care clinics through a patient-centered medical home
model. All participants were encouraged to engage in care with
a PCP if no current PCP relationship was in place.
Pharmacist-led PrEP participants presented for follow-up
visits every 3 months after PrEP initiation, and laboratory
monitoring was performed according to Centers for Disease
Control and Prevention HIV PrEP guidelines [25]. Follow-up
visits completed at a clinic-based site (university-based HIV
clinic, university-based primary care clinic, and Federally
Qualified Health Center primary care clinic) were conducted
in clinic exam rooms, and all charting and laboratory test collections were performed by each clinic’s standard procedures.
Follow-up visits conducted at the community pharmacy site occurred in a private room, and all POCT was performed at the
community pharmacy and interpreted by the pharmacist.
At all follow-up sites, a sample of whole blood by finger stick
was collected for HIV screening using a fourth-generation
HIV 1/2 Antibody/Antigen test (Alere Determine; Abbott
Laboratories, Chicago, IL), and urine, rectal, and pharyngeal specimens were obtained for Chlamydia trachomatis and
Neisseria gonorrheae by deoxyribonucleic acid probe assay
(Aptima Combo 2; Hologic, Marlborough, MA). Sexually
transmitted infection screenings for chlamydia and gonorrhea
at the community pharmacy site were self-collected by the participant. Participants provided urine specimens and were educated on self-collection of pharyngeal and rectal specimens for
STI screening. Chlamydia and gonorrhea STI specimens were
collected by the pharmacy for delivery by courier to a local
hospital-based laboratory for processing with the results reported to university-based HIV clinic clinical staff for interpretation and coordination of STI treatment if applicable.
At the community pharmacy site, whole blood by finger stick
was collected for rapid analysis of blood creatinine (i-STAT
Handheld Analyzer; Abbott Laboratories, Chicago, IL) and
Treponema palladium antibody screening (Syphilis Health
Check; Diagnostics Direct, LLC, Stone Harbor, NJ). All safety
blood tests conducted at the clinic-based sites (university-based
HIV clinic, university-based primary care clinic, and Federally
Qualified Health Center primary care clinic), including syphilis

Retention and Adherence

Almost all of the participants (55 of 60; 91.7%) chose either
the university-based HIV clinic or community pharmacy as
their preferred follow-up site (university-based HIV clinic, 28,
46.7%; community pharmacy, 27, 45%). A total of 139 P-PrEP
follow-up visits occurred over the course of the study period
totaling 30.75 person years of follow-up. There were zero HIV
seroconversions.
Retention within the P-PrEP program fell throughout the duration of the study with 73%, 58%, 43%, and 28% of the participants retained at 3, 6, 9, and 12 months, respectively. Participant
retention per site is described in Figure 1. Participants without
private insurance and those who were not MSM engaging in
unprotected anal intercourse dropped out significantly sooner
than other participants (log-rank test P = .033 and P = .001, respectively). Among participants retained throughout the study,
adherence to F/TDF remained high with a mean medication
possession ratio of 93%.

Table 1.

Baseline Characteristics of Participants

Baseline Characteristic
Age (years), mean (range)
Male

3 (5.0)

Transgender male

2 (3.3)

Transgender female

0 (0)

White

50 (83.3)

Latinx

5 (8.3)

African American

5 (8.3)

Asian or Pacific Islander

2 (3.3)

Other

1 (1.7)

Insurance Coverage, n (%)
Private/Commercial
Medicare
Medicaid
Uninsured

48 (80.0)
1 (1.7)
0 (0)
11 (18.3)

Education Completed, n (%)
Less than high school diploma or GED

0 (0)

High school diploma or GED

6 (10.2)

Some college, no degree
Two-Year Associates Degree
Bachelor Degree
Some Postgraduate education
Postgraduate or professional degree

19 (32.2)
3 (5.1)
17 (28.8)
2 (3.4)
12 (20.3)

HIV Risk Factor, n (%)b
MSM-UAI

53 (88.3)

Sexually active with HIV+ partner

17 (28.3)

Transgender person engaging in high-risk behavior

2 (3.3)

Transactional sex

1 (1.7)

Injection drug use

0 (0)

Use of stimulant (eg, methamphetamine, MDMA)

1 (1.7)

Anogenital STI within 1 year
Any Baseline Sexually Transmitted Infection, n (%)c

19 (31.7)
3 (5.0)
14 (23)

Chlamydia
Anal

9 (15.0)

Pharyngeal

0 (0)

Urogenital

1 (1.7)

Gonorrhea
Anal

4 (6.7)

Pharyngeal

6 (10.0)

Urogenital

2 (3.3)

Syphilis

Participant Satisfaction
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55 (91.7)

Female

Race and Ethnicity, n (%)a

A total of 29 STIs (11 chlamydia, 17 gonorrhea, 1 syphilis) were
diagnosed throughout the study demonstrating 0.94 incident
STI infections per person years of follow-up. The majority were
observed at the baseline visit upon P-PrEP enrollment. Overall
STI prevalence decreased over the course of the study (data not
shown).

Of the 35 participants completing the 6-month visit, a total of 29
participants completed the P-PrEP satisfaction questionnaire:
13 (44.8%) from the community pharmacy site, 16 (55.2%) from
the university-based HIV clinic site, and none from either the
university-based primary care clinic or the Federally Qualified
Health Center primary care clinic sites. All of the respondents
stated they would definitely recommend the P-PrEP program.
Respondents reported the P-PrEP program allowed for ease of
PrEP care, quick service, extended hours for follow-up visits,
and friendly and honest pharmacists. The ease of medication
access, confusion with the collection of rectal and pharyngeal
STI swabs, and delayed communication between pharmacist

34 (20–61)

Gender, n (%)

Previous nPEP prescription

Sexually Transmitted Infections

All Participants, n = 60

New diagnosis
History of infection

0 (0)
10 (17.0)

Abbreviations: GED, General Education Diploma; HIV, human immunodeficiency virus;
MDMA, 3,4-methylenedioxymethamphetamine, “Ecstasy”; MSM-UAI, men who have sex
with men-unprotected anal intercourse; nPEP, nonhealthcare HIV postexposure prophylaxis; STI, sexually transmitted infections.
NOTE: Except where indicated, data are presented as n (%) of study group participants.
a

Some participants reported multiple categories leading to unequal total proportion.

b

Some participants reported multiple categories leading to unequal total proportion.

c

Some participants reported multiple categories leading to unequal total proportion.

providers and medical providers were noted as areas needing
improvement for the P-PrEP program (Figure 2). Of the participants who completed follow-up visits at the community
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80% (48 of 60) were commercially insured, and 89.8% (54 of
60) had completed some college or higher. The mean age of
participants was 34 years (range, 20–61 years), and 88.3% (53
of 60) identified as MSM. The mean creatinine clearance was
130 mL/minute (range, 89–172 mL/minute). Fourteen participants (23%) were diagnosed with chlamydia or gonorrhea at
the baseline visit for a total number of 22 diagnosed infections.
Rectal and pharyngeal infections were most common at baseline (4 rectal gonorrhea, 9 rectal chlamydia, and 6 pharyngeal
gonorrhea). No incident syphilis infections were diagnosed at
baseline; however, 10 participants (17%) had a previous history
of syphilis infection and treatment (Table 1).

30

28

27
21

20

21
18

17

15

13

12
9

10

8
4

5

2

1

1

1

0

0

0

0
University-based HIV
Clinic

0

0

Community Pharmacy University-based Primary Community-Based
Care Clinic
Primary Care Clinic
Follow-up Site

Baseline

3 Months

6 Months

9 Months

12 Months

Figure 1. Pharmacist-led pre-exposure prophylaxis program participant totals through study duration notated separately by follow-up site. All baseline visits were conducted at the university-based human immunodeficiency virus (HIV) clinic site. The participant totals for the baseline visit is representative of the participant’s choice of
follow-up site after study entry.

pharmacy, half (6 of 12) stated they would be willing to pay at
least $20 quarterly for continued PrEP visits with the remaining
participants willing to pay up to $60 quarterly. One participant
at the community pharmacy site did not respond to the cost
consideration question.

conducting sexual histories during P-PrEP follow-up visits.
Workflow disruption at the community pharmacy site was
reported only once (0.7%) throughout the study. The mean
reported times for performing POCT, PrEP counseling, and
total visit times were 8.7, 16, and 28 minutes, respectively
(Figure 3).

Pharmacist Satisfaction

A total of 7 pharmacists (1 university-based HIV clinic, 3 community pharmacy, 1 university-based primary care clinic, and
2 Federally Qualified Health Center primary care clinic) participated in P-PrEP. The P-PrEP pharmacists felt comfortable
performing POCT at all visits except on 1 occasion (0.7%).
Furthermore, 1 pharmacist at the community pharmacy site
reported 3 occasions (2.2%) in which they felt uncomfortable

DISCUSSION

In this pilot investigation of a P-PrEP, we successfully initiated
PrEP in 60 participants at risk for HIV acquisition and found a
high overall acceptance rate by both the participants and pharmacists. These data support P-PrEP as a desirable and feasible
option for PrEP delivery and scale-up.

The ease of accessing your medication
The timeliness your lab results were communicated back to you
The way STI screenings were collected
The way your blood tests were collected
The way your pharmacists worked with the prescribing physician
Privacy of your conversation with the pharmacist
Information the pharmacist provided regarding medication side effects
Pharmacist interest in your health
0%
Very Satisfied

Satisfied

10%

20%

Neither Satisfied or Dissatisfied

30% 40% 50%
Dissatisfied

60%

70%

80%

90% 100%

Very Dissatisfied

Figure 2. Participant satisfaction with the pharmacist-led pre-exposure prophylaxis program. STI, sexually transmitted infection.
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Number of Participants

25

Comfortable counseling the patient

Visit disrupted my work flow

0%
Strongly Disagree

10%

Disagree

20%

30%

40%

Neither Agree or Disagree

50%
Agree

60%

70%

Strongly Agree

80%

90%

100%

Not Applicable

Figure 3. Pharmacist assessment of workflow disruption and comfortability with point-of-care testing and pre-exposure prophylaxis (PrEP) counseling, per pharmacist-led
PrEP visit.

Retention in care decreased over the course of the study,
with just over half retained at 6 months and approximately one
quarter retained at 12 months. Although disappointing, these
retention rates are similar to retention rates seen in other realworld PrEP implementation studies [27–29]. Furthermore,
we identified similar drivers of poor retention that included
both structural (insurance coverage) and individual (HIV risk
factor) factors. More important, a high rate of medication adherence was seen in retained participants. The effectiveness of
PrEP ultimately depends on adherence to the prescribed medication, so the high rates of adherence among those retained in
care are encouraging.
The P-PrEP follow-up visits performed at the community
pharmacy were quick and convenient for participants. The
adoption of a P-PrEP may allow for increased PrEP access in
rural settings by reducing travel times and potentially offering
a lower cost option for PrEP follow-up, which is an important
consideration in light of the Trump administration’s plan to
end the HIV epidemic [30]. Furthermore, the pharmacy may
be an acceptable setting for future PrEP formulations, such as
intramuscular cabotegravir, considering pharmacists’ current
integration into other long-acting medical treatments and vaccination administration [31–34].
The community pharmacy site used in this pilot study was a
small, independent pharmacy with significant buy-in by its pharmacists and pharmacist owner. Pharmacy workflow disruption
and leadership acceptance should be considered as potential
barriers to implementation of P-PrEPs at other sites as evident
from a recent survey of Midwest pharmacists in which concerns
of workflow disruption and acceptance by leadership were cited
as a concern, in spite of high pharmacist interest in provision
6 • OFID • Havens et al

of PrEP services [35]. In addition, the balance of cost to the patient and compensation to the pharmacy should be considered
for program sustainability. Challenges remain in pharmacist
compensation for these services because not all states allow
pharmacists to bill for professional services [15]. The One-Step
PrEP program, another P-PrEP in Seattle, Washington, was financially sustainable, but pharmacists are permitted to legally
bill Medicaid for services provided in the state, allowing this
model to be implemented more easily in Washington in comparison to states without this provision [13]. The P-PrEP participants at the community pharmacy in our study received PrEP
care, POCT, and STI screening free of charge. All participants
receiving care at a clinic-based P-PrEP site were not charged for
the PrEP visit, but all laboratory and STI screenings were billed
by standard procedures. Participants at the community pharmacy were willing to pay from $20 to $60 quarterly, amounting
to approximately the cost of the POCT supplies and allowing
for little compensation for the pharmacist’s time and effort for
PrEP services. However, additional pharmacy revenue through
F/TDF prescription reimbursements could potentially subsidize some of those costs.
Laboratory management and STI screening was a logistical
challenge at the community pharmacy site. No CLIA-waived
POC test is currently available to distinguish between previous
and incident syphilis infections nor for hepatitis B screening,
and, thus, both require venipuncture and subsequent processing
at a clinical laboratory. The PrEP@Home study used the rapid
plasma reagin card for syphilis screening (Arlington Scientific,
Inc, Springville, UT), eliminating the need for venipuncture, although it still requires processing at a clinical laboratory [7].
The collection and couriered delivery of STI specimens and
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Comfortable performing Point of Care Testing

CONCLUSIONS

Implementation of a P-PrEP is feasible with high rates of patient satisfaction and pharmacist acceptability. Its utilization
may be of specific benefit to patients living in underserved or
rural areas to increase PrEP access and allow for patient convenience. Despite concerns of patient cost, pharmacist compensation and workflow disruption, and the logistical challenges of
laboratory and STI screening, the community pharmacy should
remain a potential option for PrEP follow-up.
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